R&D Pipeline (In-House)
As of August 2010
| Development Stage |
Brand name / Development Code |
Development Classification |
Therapeutic Target |
|---|---|---|---|
| NDA | KMV-0207 | Kissei | Improvement of postprandial plasma glucose transition in patients with type 2 diabetes mellitus -Mitiglinide / Voglibose combination product - |
| Phase Ⅲ | ※1 KUC-7483 | Kissei | Overactive bladder - Beta 3 agonist - |
| Phase II | KPS-0373 | In-licensed / Shionogi(Japan) | Spinocerebellar ataxia - Non-peptide mimetic of TRH - |
| Phase I / II | YS110 | In-licensed / Y's Therapeutics, University of Tokyo, JST (Japan) | Malignant mesothelioma - Humanized anti-CD26 monoclonal antibody - |
| Phase I | KLH-2109 | Kissei | Endometriosis/ uterine fibroids - GnRH antagonist - |
| Silodosin/ KSO-0400 |
Kissei | Dysuria associated with benign prostatic hyperplasia - Alfa 1A antagonist - - Once-daily formulation - |
|
| Ozagrel/ KCT-0809 |
Co-development / Teika(Japan) | Dry-eye - Restoration of corneal and conjunctival epithelium disorder - |
※1: KUC-7483: The data of Phase Ⅲ clinical study etc are under detailed
analysis.
R&D Pipeline (Out-Licensing)
As of August 2010
| Development Stage | Generic Name / Development Code |
Development Company |
Territory | Therapeutic Target |
|---|---|---|---|---|
| Approved | Silodosin | Synmosa (Taiwan) |
Taiwan, Hong Kong | Dysuria associated with benign prostatic hyperplasia |
| NDA | Mitiglinide | Eisai (Japan) |
※1 ASEAN (10 countries) |
Type 2 diabetes |
| Silodosin | Daiichi Sankyo (Japan) |
China | Dysuria associated with benign prostatic hyperplasia | |
| Eisai (Japan) |
※2 ASEAN (10 countries), India, SriLanka | |||
| Phase III | Mitiglinide | Elixir (U.S.) |
North America, Central America, South America | Type 2 diabetes |
| USV (India) |
India | |||
| Phase II | Bedoradrine | MediciNova (U.S.) |
Worldwide, except for Japan | Status asthmatics/ Threatened premature labor |
| Tranilast | Nuon Therapeutics (U.S.) |
Worldwide, except for Japan and Korea | Rheumatoid arthritis/ Chronic hyperuricemia with gout |
|
| Phase I | KGA-3235 | Dainippon Sumitomo (Japan) |
Japan | Type 2 diabetes |
| GlaxoSmithKline (U.K.) |
Europe, USA, others | |||
| Bedoradrine | MediciNova (U.S.) |
Worldwide, except for Japan | COPD |
※2: NDA in 2 ASEAN countries
| Back |
